Teriparatide Reduces Osteoporosis Pain and Bone Loss in a Mouse Model | Research

The takeaway

Teriparatide (PTH peptide) prevents bone loss and reduces pain in ovariectomized mice by suppressing CGRP and TRPV1 expression in pain-sensing neurons.

Dual action
Teriparatide both prevented bone loss and reduced pain by suppressing neuropeptide expression in DRG neurons

What the researchers found

Teriparatide prevents ovariectomy-induced bone loss, reduces mechanical hyperalgesia, and suppresses CGRP and TRPV1 upregulation in dorsal root ganglion neurons innervating affected limbs.

Why it matters

Many osteoporosis patients suffer from chronic pain that isn't fully addressed by bone-strengthening drugs. Teriparatide uniquely treats both bone loss and associated pain by modulating neuropeptide signaling.

The numbers in context

4-week treatment; prevented bone loss on micro-CT; reduced mechanical hyperalgesia; lowered CGRP and TRPV1 expression in DRG neurons

How the study worked

Three groups of ovariectomized/sham mice, 4-week subcutaneous teriparatide treatment, von Frey filament mechanical sensitivity testing, microCT bone analysis, immunohistochemistry of DRG neurons.

Who was studied

Ovariectomized female ddY mice

What this study cannot tell us

Mouse study with unclear translation to humans. Small group sizes not specified. Only 4 weeks of treatment with no long-term follow-up.

How to read the evidence

Animal study demonstrating both bone and pain outcomes. Preliminary evidence that needs human clinical confirmation.

When this study was published

Published in 2020. Teriparatide is already clinically used for osteoporosis, making the pain findings clinically translatable.

The bigger picture

This finding positions teriparatide as a dual-action therapy for postmenopausal osteoporosis — building bone while simultaneously addressing pain through neuropeptide pathway modulation.

Questions still open

Does teriparatide reduce osteoporotic pain in human patients?
Is the pain-reducing effect sustained after treatment stops?
Could teriparatide's neuropeptide modulation help with other chronic pain conditions?

Common questions

What is teriparatide?

Teriparatide is a synthetic version of parathyroid hormone (PTH), a peptide naturally produced by the body. It's approved for treating severe osteoporosis and works by stimulating new bone formation rather than just slowing bone breakdown.

How does teriparatide reduce pain?

The study found teriparatide suppresses CGRP and TRPV1, two molecules involved in pain signaling, in the nerve cells that sense pain from bones. By reducing these pain mediators, teriparatide addresses both the structural and sensory aspects of osteoporosis.

Read the original research

Teriparatide improves pain-related behavior and prevents bone loss in ovariectomized mice.

Journal of orthopaedic surgery (Hong Kong), 28(1), 2309499019893194

View on PubMed ↗Publisher’s paper ↗

Citation

Kato, Sho; Wakabayashi, Hiroki; Nakagawa, Taro; Miyamura, Gaku; Naito, Yohei; Iino, Takahiro; Sudo, Akihiro. (2020). Teriparatide improves pain-related behavior and prevents bone loss in ovariectomized mice.. Journal of orthopaedic surgery (Hong Kong), 28(1), 2309499019893194. https://doi.org/10.1177/2309499019893194